摘要
目的对PCR-SSCP筛检非小细胞肺癌EGFR基因突变的临床价值进行评价分析。方法随机抽取在2010年1月—2012年7月间该院收治的非小细胞肺癌临床患者病例100作为研究对象,分别采取DNA测序法和PCR-SSCP法对研究对象展开EGFR基因突变检测,并将DNA测序法作为金标准,对PCR-SSCP的准确性进行评价。结果经统计得知,有DNA测序法检出32例患者中发生EGFR基因突变者31例,检出率为31.0%,经PCR-SSCP法检测出突变者34例,检出率为34.0%,两组差异不存在统计学意义(P>0.05)。结论采取PCR-SSCP法对非小细胞肺癌EGFR基因突变进行筛检的准确性较高,值得对其给予关注。
Objective To PCR-SSCP screening of non-small cell lung cancer with EGFR gene mutation clinical value analysis. Methods Sampling method in 2010 January to 2012 year in July in our hospital of non small cell lung cancer patients a case in 100 as the research object, adopt DNA sequencing method and PCR-SSCP method studied mutation detection of EGFR gene, and DNA sequencing as a gold standard, the PCR-SSCP accuracy evaluation. Results DNA sequencing method detected 32 cases occurring in patients with EGFR mutations in 31 cases, the detection rate is 31%, with PCR-SSCP method to detect mutations in 34 cases, the detection rate was 34%, the difference between the two groups is not statistically significant （P 〉 0.05）. Conclusion PCR-SSCP method in non small cell lung cancer EGFR gene mutation screening of high accuracy, worthy of the attention.
出处
《中国卫生产业》
2013年第11期11-12,共2页
China Health Industry
